Navigation Links
WuXi PharmaTech Acquires China-Based Clinical Research Services Companies
Date:10/24/2011

SHANGHAI, Oct. 24, 2011 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development services company with operations in China and the United States, today announced the acquisition of MedKey Med-Tech Development Co. Ltd. and Jiecheng Med-Tech Development Co. Ltd., two related contract clinical research services companies based in Shanghai, China. The financial terms of the transaction were not disclosed.

Founded in 2006, MedKey/Jiecheng have about 80 employees and operate in 15 cities in China, with offices in Shanghai, Beijing, and Guangzhou. The companies provide services in regulatory affairs, Phase I-IV clinical trial management, and clinical trial site management throughout most of the regions in China. Their customer base includes both multinational pharmaceutical companies and domestic Chinese pharmaceutical companies. David Xi, founder, owner, and CEO of the companies, will continue to manage MedKey/Jiecheng as WuXi's Executive Director of Clinical Operations. As part of WuXi, MedKey/Jiecheng will leverage WuXi's broad customer base and will focus on clinical services needed by customers for Chinese regulatory filings and market access.    

"WuXi's acquisition of Medkey/Jiecheng continues our strategy to build an integrated platform of R&D services that will allow anyone and any company to discover and develop drugs more efficiently and cost effectively for patients," said Dr. Ge Li, Chairman and CEO of WuXi. "This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers' growing clinical development needs in the fast-growing Chinese healthcare market."    

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnolog
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. WuXi PharmaTech Announces Second Quarter 2011 Results
2. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
3. WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
4. WuXi PharmaTech Announces First-Quarter 2011 Results
5. WuXi PharmaTech Files 2010 Annual Report on Form 20-F
6. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
7. Bristol-Myers Squibb and WuXi PharmaTech Announce Collaboration for a New Analytical and Stability Testing Facility
8. WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release
9. WuXi PharmaTech Provides Update of 2010 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
10. WuXi PharmaTech Presents 2010 Life Science and Chemistry Awards
11. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  Sage Analytics ( www.sageanalytics.com ... laboratory-quality cannabis potency measurement systems, announced its sponsorship of ... Cruise Fundraiser. A limited number of tickets are available ... help a great cause while enjoying an open bar, ... around the San Francisco Bay at sunset. ...
(Date:8/3/2015)... YORK , Aug. 3, 2015   ... global pharmaceutical company Allergan plc is ... Deloitte and Intermountain Healthcare to include ... harness ConvergeHEALTH,s OutcomesMiner analytics platform to generate real-world ... outcomes. "We look forward to expanding ...
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, ... and development agreements between biotech companies, military ... biotech solutions & therapies with regards to ... to positive clinical enhancements for regenerative medicine ... with recent developments, partnerships and advancements in ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 2ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 3ConvergeHEALTH by Deloitte and Intermountain Healthcare Expand Real World Evidence Collaboration with Allergan to Focus on Women's Health 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 2Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 3Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 4Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 5Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions 6
... 11 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 ... may access a live webcast of the presentation on our ... It is recommended that listeners log on 15 minutes early ...
... NEW YORK, Nov. 11 Pulmo BioTech Inc. (OTC ... early experimental results have indicated that its PulmoBind(TM) product ... and follow-up of many conditions that affect the physical ... results, if confirmed by further experiments, would broaden the ...
Cached Medicine Technology:Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 2Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 3Pulmo BioTech Inc. Announces that Its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) Shows Early Indications of Being Able to Diagnose a Wide Range of Medical Conditions Affecting the Physical and/or Biological Integrity of the Pulmon 4
(Date:8/3/2015)... ... 03, 2015 , ... Novatus, Inc. today launched the largest ... well as announced the date of its next major release. , Version 6.0 ... tasks as well as enhancements to the customer experience. Users now enjoy ...
(Date:8/3/2015)... ... , ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative ... Conference on Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in ... presentation may be accessed via the investor relations section of the Company’s website. , ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive ... occurs naturally in the body and helps absorb and breakdown fat cells. Previously, plastic ... These are invasive procedures and very expensive for most people. Now with Kybella, there ...
(Date:8/3/2015)... ... , ... From 2006-2017 the number of dental laboratories in ... compiled for the National Association of Dental Laboratories ( NADL ) by Valmont ... Statistics. As the number of dental laboratories decreases, dentists will have fewer options ...
(Date:8/3/2015)... ... 03, 2015 , ... Hub International Insurance Services ... joined its growing California employee benefits division. Mr. Williams will be responsible ... Mr. Williams will be joining the newly integrated Northern California employee benefits team ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... new method for creating nanofibers made of proteins, developed ... (NYU-Poly), promises to greatly improve drug delivery methods for ... as well as aid in the regeneration of human ... this same development could point the way to even ...
... Center for Healthy Neighborhoods of Case Western Reserve ... groups on three of the most pressing public ... The three data briefs statistical public health ... prevalence estimates for diabetes, hypertension awareness and obesity ...
... -- Even when fast-food restaurants list calorie counts for menu ... information to make healthy meal choices, researchers report. In ... 200 food items on menu boards from 12 restaurant chains ... often, calorie counts were listed for combo meals or meals ...
... at Moffitt Cancer Center in Tampa, Fla., and colleagues ... prevent resistance to the chemotherapy drug vemurafenib, commonly used ... characterized by a diminished apoptosis (programmed cancer cell death) ... and cell survival is regulated by a family of ...
... National Jewish Health has received a grant for $950,308 ... Colorado,s San Luis Valley with educational materials for patients ... is the most common chronic illness in children and ... days. The San Luis Valley has one of the ...
... of all deaths in the United States are linked to ... inactivity. Despite these causal links, of the $2 trillion spent ... of that is devoted to addressing behavioral and social risk ... in behavioral and social sciences with a new $500,000 grant ...
Cached Medicine News:Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:First breakdown of public health data for Cleveland neighborhoods 2Health News:First breakdown of public health data for Cleveland neighborhoods 3Health News:Many Gaps in Fast-Food Nutrition Information 2Health News:Researchers find potential solution to melanoma's resistance to vemurafenib 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 2Health News:National Jewish Health receives grant to improve care of asthma patients in the San Luis Valley 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
... Gentian violet ink ... prepping, Millimeter scale ruler ... barrel for quick measuring. ... with both inch and ...
Double-ended, one end sharp, other end blunt, 7 1/2", double-ended, 5 mm wide....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
Medicine Products: